Llwytho...
Intraokulare Entzündungen bei Brolucizumab-Anwendung: Patientenmanagement – Diagnose – Therapie
The anti-vascular endothelial growth factor (anti-VEGF) agent brolucizumab has been approved in the USA in October 2019 and in Europe in February 2020 for the treatment of neovascular age-related macular degeneration (nAMD). The approval was based on the randomized, double-blind phase III studies HA...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Ophthalmologe |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Springer Medizin
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7935813/ https://ncbi.nlm.nih.gov/pubmed/33555415 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00347-021-01321-8 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|